How the Discovery of an Alzheimer’s Tipping Point Could Improve Drug Trials
In a study, UCSF neurologist William Seeley, MD, and colleagues identified two key moments in the natural history of Alzheimer’s, pointing to a window of opportunity for treatment with amyloid-lowering drugs.
